Figge HL - Search Results

1

Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.

Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA. Kallakury BV, et al. Among authors: figge hl, figge j. Hum Pathol. 1994 Jan;25(1):92-7. doi: 10.1016/0046-8177(94)90177-5. Hum Pathol. 1994. PMID: 7508886

2

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.

Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HA. Ross JS, et al. Cancer. 1993 Nov 15;72(10):3020-8. doi: 10.1002/1097-0142(19931115)72:10<3020::aid-cncr2820721026>3.0.co;2-#. Cancer. 1993. PMID: 8106140

3

Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.

Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS. Kallakury BV, et al. Cancer. 1996 Oct 1;78(7):1461-9. doi: 10.1002/(sici)1097-0142(19961001)78:7<1461::aid-cncr13>3.0.co;2-y. Cancer. 1996. PMID: 8839552

4

E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.

Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jennings TA, Ingle R, Kim DN. Ross JS, et al. Among authors: figge hl. Mod Pathol. 1994 Oct;7(8):835-41. Mod Pathol. 1994. PMID: 7530850

5

Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma.

Kallakury BV, Jennings TA, Ross JS, Breese K, Figge HL, Fisher HA, Figge J. Kallakury BV, et al. Among authors: figge hl, figge j. Diagn Mol Pathol. 1994 Dec;3(4):227-32. doi: 10.1097/00019606-199412000-00003. Diagn Mol Pathol. 1994. PMID: 7532528

6

Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status.

Ross JS, Nazeer T, Figge HL, Fisher HA, Rifkin MD. Ross JS, et al. Among authors: figge hl. Am J Clin Pathol. 1995 Jul;104(1):36-41. doi: 10.1093/ajcp/104.1.36. Am J Clin Pathol. 1995. PMID: 7541934

7

E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.

Ross JS, del Rosario AD, Figge HL, Sheehan C, Fisher HA, Bui HX. Ross JS, et al. Among authors: figge hl. Hum Pathol. 1995 Sep;26(9):940-4. doi: 10.1016/0046-8177(95)90081-0. Hum Pathol. 1995. PMID: 7672793

8

Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.

Ambros RA, Vigna PA, Figge J, Kallakury BV, Mastrangelo A, Eastman AY, Malfetano J, Figge HL, Ross JS. Ambros RA, et al. Among authors: figge hl, figge j. Cancer. 1994 Mar 15;73(6):1686-92. doi: 10.1002/1097-0142(19940315)73:6<1686::aid-cncr2820730622>3.0.co;2-w. Cancer. 1994. PMID: 8156496

9

Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation.

Kallakury BV, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R, Figge HL, Nazeer T, Ross JS. Kallakury BV, et al. Among authors: figge hl. Mod Pathol. 1996 Jan;9(1):41-7. Mod Pathol. 1996. PMID: 8821955

10

Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two established indicators of poor prognosis.

Gerasimov G, Bronstein M, Troshina K, Alexandrova G, Dedov I, Jennings T, Kallakury BV, Izquierdo R, Boguniewicz A, Figge H, et al. Gerasimov G, et al. Exp Mol Pathol. 1995 Feb;62(1):52-62. doi: 10.1006/exmp.1995.1006. Exp Mol Pathol. 1995. PMID: 7556591

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters